Polar Capital LLP Buys 15,000 Shares of argenx SE – (ARGX)

Share on StockTwits

Polar Capital LLP grew its stake in shares of argenx SE – (NASDAQ:ARGX) by 25.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 75,000 shares of the company’s stock after acquiring an additional 15,000 shares during the period. Polar Capital LLP’s holdings in argenx were worth $7,205,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ARGX. Northern Trust Corp lifted its position in shares of argenx by 11.5% during the second quarter. Northern Trust Corp now owns 12,418 shares of the company’s stock worth $1,029,000 after acquiring an additional 1,285 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of argenx by 1,715.2% during the third quarter. JPMorgan Chase & Co. now owns 15,429 shares of the company’s stock worth $1,170,000 after acquiring an additional 14,579 shares in the last quarter. Jennison Associates LLC lifted its position in shares of argenx by 54.0% during the third quarter. Jennison Associates LLC now owns 511,221 shares of the company’s stock worth $38,771,000 after acquiring an additional 179,208 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of argenx by 12.0% during the third quarter. Janus Henderson Group PLC now owns 493,649 shares of the company’s stock worth $37,438,000 after acquiring an additional 53,070 shares in the last quarter. Finally, Artal Group S.A. lifted its position in shares of argenx by 23.3% during the third quarter. Artal Group S.A. now owns 185,000 shares of the company’s stock worth $14,030,000 after acquiring an additional 35,000 shares in the last quarter. Hedge funds and other institutional investors own 63.72% of the company’s stock.

Shares of ARGX stock opened at $130.26 on Friday. argenx SE – has a 52-week low of $63.81 and a 52-week high of $135.58. The firm has a market capitalization of $4.02 billion, a P/E ratio of -93.04 and a beta of 1.29.

A number of equities research analysts recently issued reports on the company. Zacks Investment Research downgraded argenx from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Wedbush increased their price objective on argenx from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 4th. Guggenheim assumed coverage on argenx in a research report on Friday, February 22nd. They issued a “buy” rating and a $157.00 price objective on the stock. Finally, Wolfe Research assumed coverage on argenx in a research report on Friday, December 14th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $140.91.

COPYRIGHT VIOLATION WARNING: “Polar Capital LLP Buys 15,000 Shares of argenx SE – (ARGX)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4224136/polar-capital-llp-buys-15000-shares-of-argenx-se-argx.html.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Further Reading: Cost of Debt

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stryker Co.  Expected to Post Quarterly Sales of $3.51 Billion
Stryker Co. Expected to Post Quarterly Sales of $3.51 Billion
CryptoEscudo  Trading Down 50.1% This Week
CryptoEscudo Trading Down 50.1% This Week
Horizen  Market Cap Hits $39.55 Million
Horizen Market Cap Hits $39.55 Million
Illinois Tool Works Inc.  Expected to Announce Quarterly Sales of $3.65 Billion
Illinois Tool Works Inc. Expected to Announce Quarterly Sales of $3.65 Billion
Zacks: Brokerages Expect Group 1 Automotive, Inc.  Will Announce Quarterly Sales of $2.85 Billion
Zacks: Brokerages Expect Group 1 Automotive, Inc. Will Announce Quarterly Sales of $2.85 Billion
$22.56 Million in Sales Expected for FS Bancorp Inc  This Quarter
$22.56 Million in Sales Expected for FS Bancorp Inc This Quarter


Leave a Reply

© 2006-2019 Ticker Report